Lynn Morris

Lynn Morris

Auto-generated profile, based on publicly available information

Lynn Morris

Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand; Johannesburg

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2014 in Nature
Verified
Journal Article
Closed access
PDF file
NDNicole A. Doria-Rose
Nicole A. Doria-Rose
CSChaim A. Schramm
Chaim A. Schramm
JGJason Gorman
Jason Gorman
PMPenny Moore
Penny Moore
JBJinal N. Bhiman
Jinal N. Bhiman
JMJohn R. Mascola
John R. Mascola

2 March 2021 in Nature Medicine
Verified
Journal Article
Closed access
CWConstantinos Kurt Wibmer
Constantinos Kurt Wibmer
FAFrances Ayres
Frances Ayres
THTandile Hermanus
Tandile Hermanus
MMMashudu Madzivhandila
Mashudu Madzivhandila
PKPrudence Kgagudi
Prudence Kgagudi
PMPenny Moore
Penny Moore

21 October 2012 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PMPenny Moore
Penny Moore
Elin GrayElin Gray
Elin Gray
CWConstantinos Kurt Wibmer
Constantinos Kurt Wibmer
JBJinal N Bhiman
Jinal N Bhiman
MNMolati Nonyane
Molati Nonyane
LMLynn Morris
Lynn Morris

15 March 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MBMattia Bonsignori
Mattia Bonsignori
EKEdward F. Kreider
Edward F. Kreider
DFDaniela Fera
Daniela Fera
RMR. Ryan Meyerhoff
R. Ryan Meyerhoff
TBTodd Bradley
Todd Bradley
BHBarton F. Haynes
Barton F. Haynes
Identification of maturation stages of V3-glycan neutralizing antibodies explains the long duration required for their development.

15 June 2007 in Journal of Virology
Verified
Journal Article
Closed access
Elin GrayElin Gray
Elin Gray
PMPenny Moore
Penny Moore
ICI. A. Choge
I. A. Choge
JDJ. M. Decker
J. M. Decker
FBF. Bibollet-Ruche
F. Bibollet-Ruche
LML. Morris
L. Morris
The study of the evolution and specificities of neutralizing antibodies during the course of human immunodeficiency virus type 1 (HIV-1) infection may be important in the discovery of possible targets for vaccine design. In this study, we assessed the autologous and heterologous neutralization responses of 14 HIV-1 subtype C-infected individuals, using envelope clones obtained within the first 2 months postinfection. Our data show that potent but relatively strain-specific neutralizing antibodies develop within 3 to 12 months of HIV-1 infection. The magnitude of this response was associated with shorter V1-to-V5 envelope lengths and fewer glycosylation sites, particularly in the V1-V2 region. Anti-MPER antibodies were detected in 4 of 14 individuals within a year of infection, while antibodies to CD4-induced (CD4i) epitopes developed to high titers in 12 participants, in most cases before the development of autologous neutralizing antibodies. However, neither anti-MPER nor anti-CD4i antibody specificity conferred neutralization breadth. These data provide insights into the kinetics, potency, breadth, and epitope specificity of neutralizing antibody responses in acute HIV-1 subtype C infection.

18 September 2009 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
PMPenny Moore
Penny Moore
NRNthabeleng Ranchobe
Nthabeleng Ranchobe
BLBronwen E. Lambson
Bronwen E. Lambson
Elin GrayElin Gray
Elin Gray
ECEleanor Cave
Eleanor Cave
LMLynn Morris
Lynn Morris
We previously showed that HIV-1 subtype C viruses elicit potent but highly type-specific neutralizing antibodies (nAb) within the first year of infection. In order to determine the specificity and evolution of these autologous nAbs, we examined neutralization escape in four individuals whose responses against the earliest envelope differed in magnitude and potency. Neutralization escape occurred in all participants, with later viruses showing decreased sensitivity to contemporaneous sera, although they retained sensitivity to new nAb responses. Early nAb responses were very restricted, occurring sequentially and targeting only two regions of the envelope. In V1V2, limited amino acid changes often involving indels or glycans, mediated partial or complete escape, with nAbs targeting the V1V2 region directly in 2 cases. The alpha-2 helix of C3 was also a nAb target, with neutralization escape associated with changes to positively charged residues. In one individual, relatively high titers of anti-C3 nAbs were required to drive genetic escape, taking up to 7 weeks for the resistant variant to predominate. Thereafter titers waned but were still measurable. Development of this single anti-C3 nAb specificity was associated with a 7-fold drop in HIV-1 viral load and a 4-fold rebound as the escape mutation emerged. Overall, our data suggest the development of a very limited number of neutralizing antibody specificities during the early stages of HIV-1 subtype C infection, with temporal fluctuations in specificities as escape occurs. While the mechanism of neutralization escape appears to vary between individuals, the involvement of limited regions suggests there might be common vulnerabilities in the HIV-1 subtype C transmitted envelope. Most HIV-1 infected individuals develop neutralizing antibodies against their own virus, termed an autologous neutralizing response. It is known that this response exerts pressure on the envelope of HIV, the target of such antibodies, resulting in neutralization escape. Here we have identified the targets of these antibodies and the precise genetic basis of neutralization escape in 4 individuals infected with HIV-1 subtype C. We show that V1V2 is commonly involved in escape, and that the C3 region is also a target in some cases. The latter observation confirms this region is exposed in subtype C, unlike subtype B. We show that neutralization escape is conferred by a few amino acid mutations, some of which are outside the antibody target site. Moreover, escape from these limited specificities even within a single individual occurs via a variety of different pathways involving substitutions, indels and glycan shifts. The finding in 2 individuals that an anti-C3 response developed first, followed by an anti-V1V2 response, suggests there may be specific regions of envelope particularly vulnerable to antibody neutralization. Overall, we propose a mechanistic explanation for how HIV-1 epitopes drive sequential waves of neutralization escape in early subtype C infection.